266 results on '"Moreau, P. A."'
Search Results
2. P18 Adjusted Comparison of Teclistamab Versus Real-World Physician’s Choice (RWPC) of Therapy in Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
3. Biais cognitifs en rhumatologie
4. CO93 Matching-Adjusted Indirect Treatment Comparison (MAIC) of Teclistamab Versus Selinexor-Dexamethasone for the Treatment of Patients with Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM)
5. LONG-TERM OUTCOMES WITH ISATUXIMAB-CARFILZOMIB-DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA PATIENTS WITH 1Q21+ STATUS: UPDATED RESULTS FROM THE PHASE 3 IKEMA STUDY
6. Identification of heat transfer coefficient including radiative effects at the glass/mold interface
7. Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study
8. Single-cell and spatial characterization of ischemic heart disease and heart failure from ex-vivo biopsies reveals inflammatory and vascular changes in the right atrium
9. The versatile fueling systems of WEST
10. MO-0949 Phase 1 study of escalated total marrow irradiation and melphalan at 1st relapse in multiple myeloma
11. International round robin test of environmentally benign lubricants for cold forging
12. Résultats préliminaires de l’étude exploratoire de phase 2 utilisant la TEP au 68GaPentixaFor pour le bilan initial des patients atteints de myélome multiple (MM) symptomatiques
13. Cell size and actin architecture determine force generation in optogenetically activated cells
14. La méningite rhumatoïde, une complication indépendante de la durée d’évolution et de l’activité de la PR, avec un pronostic souvent favorable : une étude du CRI
15. UPDATED PROGRESSION-FREE SURVIVAL AND DEPTH OF RESPONSE IN IKEMA, A RANDOMIZED PHASE 3 TRIAL OF ISATUXIMAB, CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED MULTIPLE MYELOMA
16. Emissivity measurement of the ITER-like plasma facing components of the WEST phase 2: Pre-exposure measurements and first WEST exposure
17. Corrigendum to “Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’”
18. VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)
19. Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study
20. Managing hematological cancer patients during the COVID-19 pandemic: an ESMO-EHA Interdisciplinary Expert Consensus
21. Cas très rare de probable lymphome intravasculaire à grandes cellules B
22. Corrigendum to ‘Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’
23. ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: IKEMA SUBGROUP ANALYSIS
24. Topic: AS08-Treatment/AS08h-Allogeneic hematopoietic cell transplantation -Bridging to transplantation
25. Thermal loads in gaps between ITER divertor monoblocks: First lessons learnt from WEST
26. Isatuximab Plus Carfilzomib and Dexamethasone Versus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma Patients Who Previously Underwent Transplantation: Ikema Subgroup Analysis
27. PO-82 Impede VTE vs saved scores to predict the risk of venous thromboembolism in newly diagnosed multiple myeloma with immunomodulatory drugs: how to choose?
28. Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
29. Évolution de l’infection à SARS-CoV-2/COVID-19 dans une cohorte de 19 patients avec rhumatismes inflammatoires chroniques traités par DMARDs
30. In-situ assessment of the emissivity of tungsten plasma facing components of the WEST tokamak
31. ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (IKEMA): INTERIM ANALYSIS OF A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY
32. ISATUXIMAB PLUS POMALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND SOFT-TISSUE PLASMACYTOMAS: ICARIA-MM SUBGROUP ANALYSIS
33. Présentation atypique d’une tumeur laryngée
34. POMALIDOMIDE, BORTEZOMIB, DEXAMETHASONE AFTER 1 PRIOR LINE OF THERAPY IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: SUBANALYSIS OF OPTIMMISM BY AGE, PRIOR TRANSPLANT, AND HIGH-RISK CYTOGENETICS
35. Atypical presentation of a laryngeal tumour
36. Isatuximab plus carfilzomib and dexamethasone vs. carfilzomib and dexamethasone in relapsed/refractory multiple myeloma (ikema): interim analysis of a phase 3, randomized, open-label study
37. Remote experiment with WEST from ITER Remote Experimentation Centre
38. Analysis of lubricant performance in punching and blanking
39. ACCESS TO EARLY CLINICAL TRIALS IN OLDER PATIENTS IN FRANCE: AN ANALYSIS OF THE EGALICAN 2 STUDY
40. PCN221 HEALTHCARE RESOURCE UTILIZATION ASSOCIATED WITH DIFFERENT TREATMENT MODALITIES IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN FOUR EUROPEAN COUNTRIES: FINDINGS FROM PREAMBLE
41. The WEST plasma control system: Integration, commissioning and operation on first experimental campaigns
42. First heat flux estimation in the lower divertor of WEST with embedded thermal measurements
43. Software quality management approach for WEST CODAC
44. Early warning sensors for monitoring mercury in water
45. Utilisation du daratumumab en ATU et post ATU en France : une étude rétrospective à partir des bases de données médico-administratives hospitalières françaises (PMSI-MCO)
46. Prédiction de la progression chez des patients atteints de myélome multiple avec des Random Survival Forest
47. Renewal of the interfero-polarimeter diagnostic for WEST
48. Carfilzomib-Dexamethasone Versus Bortezomib-Dexamethasone in Relapsed or Refractory Multiple Myeloma: Updated Overall Survival, Safety, and Subgroups
49. Myélomes
50. Recommandations et référentiels
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.